Jin Bu Huan
This article was originally published in The Tan Sheet
Executive Summary
FDA's Office of Health Affairs issues March 18 memorandum to agency field offices outlining the potential health risks associated with Jin Bu Huan and asking field officers to report where the herbal product is sold. The memo was sent out to gauge how widely available the herbal product is so that FDA can determine what type of action is necessary. To date, Jin Bu Huan has been located in Los Angeles, San Francisco, Minneapolis/St. Paul and Denver, FDA said. The California health department recently issued a warning on the risk of hepatitis associated with Jin Bu Huan ("The Tan Sheet" March 28, p. 27)
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning